# Vasculata 2024

> **NIH NIH R13** · STANFORD UNIVERSITY · 2024 · $34,500

## Abstract

SUMMARY
Since 2004, Vasculata conferences have been convening across various academic institutions in the United
States. This conference falls under the auspices of the North American Vascular Biology Organization (NAVBO),
and the NAVBO Education Committee selects the hosting site for each year. At their last meeting, the committee
unanimously chose Stanford University as the host of the 2024 meeting. This meeting has steadily grown over
the years from 60 attendees in 2004 to 120 attendees in its 2017 version at University of Illinois at Chicago.
Vasculata in a nutshell is an intense “boot camp” that introduces students and fellows to vascular biology.
Emphasis of the host site (Stanford University) is on short seminars covering a defined curriculum and reading
assignments in the original literature. Contact with local faculty and fellows, including within workshops and
poster sessions, is a critical aspect of the course. The meeting will be hosted at Stanford University and will
introduce the local academic environment, especially vascular biology minded researchers, to the scientific
community. Stanford University, University of California San Francisco (UCSF) and University of California
Berkeley (UC Berkeley) have a rich history of cardiovascular and cerebrovascular research as well as the
development of cutting-edge techniques in biological sciences and at this meeting will disseminate the
knowledge and expertise to the community. The Bay Area and Silicon Valley is known for translating discoveries
into clinical applications and the third day of the meeting will be devoted to approaches to translate basic research
findings into the clinic. Training next generation scientists and underrepresented minorities in vascular research
is a key objective, and will be facilitated at this conference. Researchers from the Bay Area study a variety of
topics including endothelial cell biology, pulmonary and cerebro-vascular disease, induced pluripotent stem cells
as preclinical tools for high-throughput screening, disease modeling and drug testing, pediatric pulmonary
circulation, congenital heart defect, blood-vascular interface, immune-vascular interface, 3D deep tissue
imaging, drug-repurposing and vascular malformation research. Stanford Healthcare and Lucile Packard
Children’s hospital Stanford are home to a comprehensive vascular anomaly clinic for over 20 years and both,
Stanford and UCSF, are Centers of Excellence for Hereditary Hemorrhagic Telangiectasia. All these areas of
research are of interest and directly relevance to the NHLBI mission. Further, training, dissemination of new
knowledge through workshops and presentations, and providing career-related information to trainees fit with
the education mission of NHLBI.

## Key facts

- **NIH application ID:** 10907355
- **Project number:** 1R13HL174104-01
- **Recipient organization:** STANFORD UNIVERSITY
- **Principal Investigator:** Edda Frauke Spiekerkoetter
- **Activity code:** R13 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $34,500
- **Award type:** 1
- **Project period:** 2024-06-01 → 2025-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10907355

## Citation

> US National Institutes of Health, RePORTER application 10907355, Vasculata 2024 (1R13HL174104-01). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10907355. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*